HIMS / Hims & Hers Health, Inc. (HIMS) CEO Andrew Dudum on Q2 2022 Results - Earnings Call Transcript

While HIMS showcases robust performance, its ability to navigate and mitigate associated risks will be pivotal in securing its future success. Major r more_horizontal

Hims & Hers Health offers personalized and customized telehealth services, specializing in niche treatments for hair loss, erectile dysfunction, skinc more_horizontal

Hims & Hers is cutting prices, but profit margins are rising. The company is cash flow positive, with plenty of cash on the balance sheet. more_horizontal

Hims & Hers reported strong earnings and raised its full-year guidance, but its stock continues to decline. Hims & Hers is focusing on personalization more_horizontal

Hims & Hers Health, Inc. is rapidly growing and becoming more profitable, making it a cheaply valued stock with minimal risk. A recent short report qu more_horizontal

Hims & Hers managed to grow revenue every year by at least 80%. However, it's still trading below its initial price when became publicly traded via SP more_horizontal

Hims & Hers Health went public through a SPAC merger a couple of years ago. Since then, the stock is down 60%. more_horizontal

Hims & Hers Health reported a strong Q2 and raised guidance, but the stock has sold off sharply. The company is expanding into new product categories more_horizontal